Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1986 Mar;49(3):265–272. doi: 10.1136/jnnp.49.3.265

The role of myo-inositol in multiple sclerosis.

G B Young, W J Hader, M Hiscock, K G Warren, D Logan
PMCID: PMC1028725  PMID: 3007676

Abstract

Myo-inositol was given orally to nine multiple sclerosis patients and nine healthy control subjects. Pattern reversal evoked potential testing was used to assess its effect. The principal positive wave increased in amplitude, duration and area in a dose-dependent manner in the multiple sclerosis group compared with controls. Cerebrospinal fluid concentrations of myo-inositol in multiple sclerosis and controls were similar. The significance of these observations is discussed in relation to recent discoveries in inositol phospholipid function.

Full text

PDF
265

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BORNSTEIN M. B., CRAIN S. M. FUNCTIONAL STUDIES OF CULTURED BRAIN TISSUES AS RELATED TO "DEMYELINATIVE DISORDERS". Science. 1965 May 28;148(3674):1242–1244. doi: 10.1126/science.148.3674.1242. [DOI] [PubMed] [Google Scholar]
  2. Berridge M. J., Dawson R. M., Downes C. P., Heslop J. P., Irvine R. F. Changes in the levels of inositol phosphates after agonist-dependent hydrolysis of membrane phosphoinositides. Biochem J. 1983 May 15;212(2):473–482. doi: 10.1042/bj2120473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bostock H., Sears T. A. The internodal axon membrane: electrical excitability and continuous conduction in segmental demyelination. J Physiol. 1978 Jul;280:273–301. doi: 10.1113/jphysiol.1978.sp012384. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bostock H., Sherratt R. M., Sears T. A. Overcoming conduction failure in demyelinated nerve fibres by prolonging action potentials. Nature. 1978 Jul 27;274(5669):385–387. doi: 10.1038/274385a0. [DOI] [PubMed] [Google Scholar]
  5. Callaghan N., Feely M., Duggan F., O'Callaghan M., Seldrup J. The effect of anticonvulsant drugs which induce liver microsomal enzymes on derived and ingested phenobarbitone levels. Acta Neurol Scand. 1977 Jul;56(1):1–6. doi: 10.1111/j.1600-0404.1977.tb01403.x. [DOI] [PubMed] [Google Scholar]
  6. Cerf J. A., Carels G. Multiple sclerosis: serum factor producing reversible alterations in bioelectric responses. Science. 1966 May 20;152(3725):1066–1068. doi: 10.1126/science.152.3725.1066. [DOI] [PubMed] [Google Scholar]
  7. Crain S. M., Bornstein M. B. Depression of complex bioelectric discharges in cerebral tissue cultures by thermolabile complement-dependent serum factors. Exp Neurol. 1975 Oct;49(1 Pt 1):330–335. doi: 10.1016/0014-4886(75)90216-2. [DOI] [PubMed] [Google Scholar]
  8. Davis F. A., Schauf C. L. Neural blocking activity of multiple sclerosis and EAE sera. Neurology. 1976 Jun;26(6 Pt 2):43–44. doi: 10.1212/wnl.26.6_part_2.43. [DOI] [PubMed] [Google Scholar]
  9. Dawson R. M., Hemington N., Irvine R. F. The inhibition and activation of Ca2+-dependent phosphatidylinositol phosphodiesterase by phospholipids and blood plasma. Eur J Biochem. 1980 Nov;112(1):33–38. doi: 10.1111/j.1432-1033.1980.tb04983.x. [DOI] [PubMed] [Google Scholar]
  10. Downes C. P. Receptor-stimulated inositol phospholipid metabolism in the central nervous system. Cell Calcium. 1982 Oct;3(4-5):413–428. doi: 10.1016/0143-4160(82)90027-6. [DOI] [PubMed] [Google Scholar]
  11. Eisen A., Yufe R., Trop D., Campbell I. Reduced neuromuscular transmission safety factor in multiple sclerosis. Neurology. 1978 Jun;28(6):598–602. doi: 10.1212/wnl.28.6.598. [DOI] [PubMed] [Google Scholar]
  12. GARCIA-BUNUEL L., GARCIA-BUNUEL M. CEREBROSPINAL FLUID LEVELS OF FREE MYOINOSITOL IN SOME NEUROLOGICAL DISORDERS. Neurology. 1965 Apr;15:348–350. doi: 10.1212/wnl.15.4.348. [DOI] [PubMed] [Google Scholar]
  13. Halliday A. M., McDonald W. I., Mushin J. Visual evoked response in diagnosis of multiple sclerosis. Br Med J. 1973 Dec 15;4(5893):661–664. doi: 10.1136/bmj.4.5893.661. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hawthorne J. N. Is phosphatidylinositol now out of the calcium gate? Nature. 1982 Jan 28;295(5847):281–282. doi: 10.1038/295281a0. [DOI] [PubMed] [Google Scholar]
  15. Holm V. Inositol in multiple sclerosis. Arch Neurol. 1978 Jul;35(7):478–478. doi: 10.1001/archneur.1978.00500310080018. [DOI] [PubMed] [Google Scholar]
  16. LARRABEE M. G., LEICHT W. S. METABOLISM OF PHOSPHATIDYL INOSITOL AND OTHER LIPIDS IN ACTIVE NEURONES OF SYMPATHETIC GANGLIA AND OTHER PERIPHERAL NERVOUS TISSUES. THE SITE OF THE INOSITIDE EFFECT. J Neurochem. 1965 Jan;12:1–13. doi: 10.1111/j.1471-4159.1965.tb10245.x. [DOI] [PubMed] [Google Scholar]
  17. Lumsden C. E., Howard L., Aparicio S. R., Bradbury M. Anti-synaptic antibody in allergic encephalomyelitis. II. The synapse-blocking effects in tissue culture of demyelinating sera from experimental allergic encephalomyelitis. Brain Res. 1975 Aug 8;93(2):283–299. doi: 10.1016/0006-8993(75)90351-0. [DOI] [PubMed] [Google Scholar]
  18. Marx J. L. A new view of receptor action. Science. 1984 Apr 20;224(4646):271–274. doi: 10.1126/science.6143399. [DOI] [PubMed] [Google Scholar]
  19. Nishizuka Y. The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature. 1984 Apr 19;308(5961):693–698. doi: 10.1038/308693a0. [DOI] [PubMed] [Google Scholar]
  20. SCHUMACHER G. A., BEEBE G., KIBLER R. F., KURLAND L. T., KURTZKE J. F., MCDOWELL F., NAGLER B., SIBLEY W. A., TOURTELLOTTE W. W., WILLMON T. L. PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS. Ann N Y Acad Sci. 1965 Mar 31;122:552–568. doi: 10.1111/j.1749-6632.1965.tb20235.x. [DOI] [PubMed] [Google Scholar]
  21. Schauf C. L., Davis F. A., Sack D. A., Reed B. J., Kesler R. L. Neuroelectric blocking factors in human and animal sera evaluated using the isolated frog spinal cord. J Neurol Neurosurg Psychiatry. 1976 Jul;39(7):680–685. doi: 10.1136/jnnp.39.7.680. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Seil F. J., Leiman A. L., Kelly J. M., 3rd Neuroelectric blocking factors in multiple sclerosis and normal human sera. Arch Neurol. 1976 Jun;33(6):418–422. doi: 10.1001/archneur.1976.00500060024006. [DOI] [PubMed] [Google Scholar]
  23. Simmons D. A., Winegrad A. I., Martin D. B. Significance of tissue myo-inositol concentrations in metabolic regulation in nerve. Science. 1982 Aug 27;217(4562):848–851. doi: 10.1126/science.6285474. [DOI] [PubMed] [Google Scholar]
  24. Waxman S. G., Brill M. H. Conduction through demyelinated plaques in multiple sclerosis: computer simulations of facilitation by short internodes. J Neurol Neurosurg Psychiatry. 1978 May;41(5):408–416. doi: 10.1136/jnnp.41.5.408. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Waxman S. G. Prerequisites for conduction in demyelinated fibers. Neurology. 1978 Sep;28(9 Pt 2):27–33. doi: 10.1212/wnl.28.9_part_2.27. [DOI] [PubMed] [Google Scholar]
  26. Winegrad A. I., Greene D. A. Diabetic polyneuropathy: the importance of insulin deficiency, hyperglycemia and alterations in myoinositol metabolism in its pathogenesis. N Engl J Med. 1976 Dec 16;295(25):1416–1421. doi: 10.1056/NEJM197612162952507. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES